Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.57 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717135 | 1.00 | SLC6A4 (0.57) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL25602859 | 1.00 | SLC6A4 (0.57) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL30805855 | 1.00 | SLC6A4 (0.57) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL31320831 | 0.84 | TSHR (0.48) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL13310394 | 0.84 | HRH3 (0.47) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL25456799 | 0.84 | TSHR (0.48) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL3390351 | 0.84 | HRH3 (0.47) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL4134712 | 0.84 | TSHR (0.48) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL30967761 | 0.84 | TSHR (0.48) | SLC6A4SLC6A3KDM1AHRH3TSHR | |
| SCHEMBL29237753 | 0.84 | TSHR (0.48) | SLC6A4SLC6A3KDM1AHRH3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291523-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-1565464-B1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-07-23 | — | — | EP | disclosed |
| US-7342024-B2 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROST CANADA LTD. (CA) | 2008-03-11 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-03-16 | — | — | US | disclosed |
| EP-1565464-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-24 | — | — | EP | disclosed |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2005-05-19 | — | — | US | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NCOA3 | SLC6A4 2320/4885SLC6A3 2749/4885KDM1A 2603/4885 |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | SLC6A4 2766/4885SLC6A3 4458/4885KDM1A 2253/4885 |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | SLC6A4 2595/4885SLC6A3 3203/4885KDM1A 2474/4885 |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | SLC6A4 2766/4885SLC6A3 4458/4885KDM1A 2253/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | SLC6A4 2612/4885SLC6A3 4309/4885KDM1A 2432/4885 |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | SLC6A4 1268/4885SLC6A3 2344/4885KDM1A 576/4885 |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | SLC6A4 1094/4885SLC6A3 2075/4885KDM1A 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.